{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:52:08Z","timestamp":1791215528797,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijid.2026.108849","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:02:09Z","timestamp":1780329729000},"page":"108849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identifying barriers to hepatitis C virus elimination in the era of direct-acting antivirals"],"prefix":"10.1016","volume":"170","author":[{"given":"Thomas","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Houlihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Herraghty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessa","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannyn","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Coghlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepta","family":"Merry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona","family":"Ni Cheallaigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"Bannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7089-0665","authenticated-orcid":false,"given":"Liam","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108849_bib0001","series-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030","year":"2022"},{"key":"10.1016\/j.ijid.2026.108849_bib0002","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108849_bib0003","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108849_bib0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2468-1253(16)30182-0","article-title":"Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study","volume":"2","author":"Islam","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108849_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S2468-1253(24)00442-4","article-title":"Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis","volume":"10","author":"Artenie","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108849_bib0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CLEP.S43926","article-title":"Socioeconomic status in HCV infected patients\u2013risk and prognosis","volume":"5","author":"Omland","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ijid.2026.108849_bib0007","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/cid\/cit302","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"57","author":"Robaeys","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108849_bib0008","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.ijid.2026.108849_bib0009","doi-asserted-by":"crossref","first-page":"ofaf302","DOI":"10.1093\/ofid\/ofaf302","article-title":"Simplified and integrated HCV testing and treatment algorithm for unhoused people who inject drugs","volume":"12","author":"Ramers","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108849_bib0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.aohep.2018.06.001","article-title":"Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic","volume":"18","author":"Malespin","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ijid.2026.108849_bib0011","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12916-024-03699-z","article-title":"Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination","volume":"22","author":"Zar\u0119bska-Michaluk","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.ijid.2026.108849_bib0012","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jvh.13228","article-title":"Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies","volume":"27","author":"Darvishian","year":"2020","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.ijid.2026.108849_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000396","article-title":"Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C","volume":"7","author":"Isfordink","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.ijid.2026.108849_bib0014","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2026.108849_bib0015","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108849_bib0016","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiad463","article-title":"Molecular point-of-care testing for hepatitis C: available technologies, pipeline, and promising future directions","volume":"229","author":"Ivanova Reipold","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108849_bib0017","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.sapharm.2019.04.004","article-title":"Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: a qualitative study","volume":"16","author":"Gunn","year":"2020","journal-title":"Res Soc Adm Pharm"},{"issue":"3","key":"10.1016\/j.ijid.2026.108849_bib0018","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/add.14012","article-title":"Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis","volume":"113","author":"Platt","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.ijid.2026.108849_bib0019","doi-asserted-by":"crossref","unstructured":"Townsend L, Herraghty F, Brennan S, Grant C, Wang W, Moriarty A, et al. Outcomes ten years after implementing an emergency department opt-out blood-borne virus screening programme. Open Forum Infect Dis. 12;ofaf547.","DOI":"10.1093\/ofid\/ofaf547"},{"key":"10.1016\/j.ijid.2026.108849_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.drugalcdep.2017.11.031","article-title":"Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs","volume":"185","author":"Schackman","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ijid.2026.108849_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12879-024-08982-1","article-title":"Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol","volume":"24","author":"Klaman","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2026.108849_bib0022","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/eri.11.26","article-title":"Social inclusion and hepatitis C: exploring new possibilities for prevention","volume":"9","author":"Treloar","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2026.108849_bib0023","doi-asserted-by":"crossref","unstructured":"Gonzalez Corro LA, Zook K, Landry M, Rosecrans A, Harris R, Gaskin D, et al. An analysis of social determinants of health and their implications for hepatitis C virus treatment in people who inject drugs: the case of Baltimore. Open Forum Infect Dis. 11:ofae107.","DOI":"10.1093\/ofid\/ofae107"},{"key":"10.1016\/j.ijid.2026.108849_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hex.13400","article-title":"Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review","volume":"25","author":"Paisi","year":"2022","journal-title":"Health Expect"},{"key":"10.1016\/j.ijid.2026.108849_bib0025","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2468-2667(24)00275-5","article-title":"Improving implementation of needle and syringe programmes to expand, scale up, and sustain evidence-based prevention interventions for HIV and hepatitis C in prisons","volume":"10","author":"Kronfli","year":"2025","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ijid.2026.108849_bib0026","doi-asserted-by":"crossref","unstructured":"Evans DB, Hsu J, Boerma T Universal health coverage and universal access, 91. Bull World Health Organ, 2013, p. 546-546A.","DOI":"10.2471\/BLT.13.125450"},{"key":"10.1016\/j.ijid.2026.108849_bib0027","first-page":"1","article-title":"Suitability and acceptability of decentralised care for people living with HIV","author":"Dixon","year":"2026","journal-title":"AIDS Behav"},{"key":"10.1016\/j.ijid.2026.108849_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016420","article-title":"Usage of unscheduled hospital care by homeless individuals in Dublin, Ireland: a cross-sectional study","volume":"7","author":"Cheallaigh","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijid.2026.108849_bib0029","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.2105\/AJPH.2013.301421","article-title":"Health care utilization patterns of homeless individuals in Boston: preparing for Medicaid expansion under the affordable care act","volume":"103","author":"Bharel","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ijid.2026.108849_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13011-023-00527-0","article-title":"Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study","volume":"18","author":"Ydreborg","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"10.1016\/j.ijid.2026.108849_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.51821\/84.2.311","article-title":"Uptake of hepatitis C virus screening and treatment in persons under opioid substitution therapy between 2008 and 2013 in Belgium","volume":"84","author":"Busschots","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.ijid.2026.108849_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jgh.12864","article-title":"Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care","volume":"30","author":"Fragomeli","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ijid.2026.108849_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2026.108575","article-title":"Emergency department screening reveals declining HCV viraemia but stable HBV prevalence in Western Europe: a sentinel surveillance opportunity","volume":"167","author":"Vargas-Accarino","year":"2026","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108849_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1118227","article-title":"A systematic review of barriers and facilitators for hepatitis B and C screening among migrants in the EU\/EEA region","volume":"11","author":"Moonen","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijid.2026.108849_bib0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14659891.2019.1704076","article-title":"Engagement in the hepatitis C care continuum among people who use drugs","volume":"25","author":"Tofighi","year":"2020","journal-title":"J Subst Use"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226004844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:59:24Z","timestamp":1791212364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226004844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S1201971226004844"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108849","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying barriers to hepatitis C virus elimination in the era of direct-acting antivirals","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108849"}}